Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Tóm tắt
Từ khóa
Tài liệu tham khảo
Pappas, 2009, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis, 48, 503, 10.1086/596757
Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD
US GRADE Network, Approach and implications to rating the quality of evidence and strength of recommendations using the GRADE methodology
Magill, 2014, Multistate point-prevalence survey of health care-associated infections, N Engl J Med, 370, 1198, 10.1056/NEJMoa1306801
Wisplinghoff, 2004, Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study, Clin Infect Dis, 39, 309, 10.1086/421946
Gudlaugsson, 2003, Attributable mortality of nosocomial candidemia, revisited, Clin Infect Dis, 37, 1172, 10.1086/378745
Pappas, 2003, A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients, Clin Infect Dis, 37, 634, 10.1086/376906
Pfaller, 2012, Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004–2008, Diagn Microbiol Infect Dis, 74, 323, 10.1016/j.diagmicrobio.2012.10.003
Diekema, 2012, The changing epidemiology of healthcare-associated candidemia over three decades, Diagn Microbiol Infect Dis, 73, 45, 10.1016/j.diagmicrobio.2012.02.001
Pfaller, 2011, Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009), Int J Antimicrob Agents, 38, 65, 10.1016/j.ijantimicag.2011.02.016
Pfaller, 2011, Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009, Antimicrob Agents Chemother, 55, 561, 10.1128/AAC.01079-10
Pfaller, 2011, Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009), J Clin Microbiol, 49, 396, 10.1128/JCM.01398-10
Morgan, 2005, Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance, Infect Control Hosp Epidemiol, 26, 540, 10.1086/502581
Kollef, 2012, Septic shock attributed to Candida infection: importance of empiric therapy and source control, Clin Infect Dis, 54, 1739, 10.1093/cid/cis305
Grim, 2012, Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes, J Antimicrob Chemother, 67, 707, 10.1093/jac/dkr511
Ostrosky-Zeichner, 2011, Early treatment of candidemia in adults: a review, Med Mycol, 49, 113, 10.3109/13693786.2010.512300
Morrell, 2005, Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality, Antimicrob Agents Chemother, 49, 3640, 10.1128/AAC.49.9.3640-3645.2005
Garey, 2006, Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study, Clin Infect Dis, 43, 25, 10.1086/504810
Andes, 2012, Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials, Clin Infect Dis, 54, 1110, 10.1093/cid/cis021
Clancy, 2013, Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care, Clin Infect Dis, 56, 1284, 10.1093/cid/cit006
Rex, 1994, A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute, N Engl J Med, 331, 1325, 10.1056/NEJM199411173312001
Rex, 2003, A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects, Clin Infect Dis, 36, 1221, 10.1086/374850
Kullberg, 2005, Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial, Lancet, 366, 1435, 10.1016/S0140-6736(05)67490-9
Krause, 2004, A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis, Clin Infect Dis, 39, 770, 10.1086/423378
Mora-Duarte, 2002, Comparison of caspofungin and amphotericin B for invasive candidiasis, N Engl J Med, 347, 2020, 10.1056/NEJMoa021585
Kuse, 2007, Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial, Lancet, 369, 1519, 10.1016/S0140-6736(07)60605-9
Reboli, 2007, Anidulafungin versus fluconazole for invasive candidiasis, N Engl J Med, 356, 2472, 10.1056/NEJMoa066906
Pappas, 2007, Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis, Clin Infect Dis, 45, 883, 10.1086/520980
Anaissie, 1996, Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study, Am J Med, 101, 170, 10.1016/S0002-9343(96)80072-6
Ruhnke, 2012, Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients, Clin Microbiol Infect, 18, 680, 10.1111/j.1469-0691.2012.03784.x
Reboli, 2011, Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome, BMC Infect Dis, 11, 261, 10.1186/1471-2334-11-261
Betts, 2009, A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis, Clin Infect Dis, 48, 1676, 10.1086/598933
Nucci, 2014, An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America, Mycoses, 57, 12, 10.1111/myc.12094
Vazquez, 2014, Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial, BMC Infect Dis, 14, 97, 10.1186/1471-2334-14-97
Alexander, 2013, Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations, Clin Infect Dis, 56, 1724, 10.1093/cid/cit136
Lewis, 2013, Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure, Antimicrob Agents Chemother, 57, 4559, 10.1128/AAC.01144-13
Castanheira, 2014, Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates, Antimicrob Agents Chemother, 58, 577, 10.1128/AAC.01674-13
Lortholary, 2011, Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients, Antimicrob Agents Chemother, 55, 532, 10.1128/AAC.01128-10
Guyatt, 2011, GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology, J Clin Epidemiol, 64, 380, 10.1016/j.jclinepi.2010.09.011
Girmenia, 2001, Nephrotoxicity of amphotericin B desoxycholate, Clin Infect Dis, 33, 915, 10.1086/322716
Wingard, 1999, Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis, Clin Infect Dis, 29, 1402, 10.1086/313498
Safdar, 2010, Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis, Medicine (Baltimore), 89, 236, 10.1097/MD.0b013e3181e9441b
Walsh, 1998, Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases, Clin Infect Dis, 26, 1383, 10.1086/516353
Groll, 2000, Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system, J Infect Dis, 182, 274, 10.1086/315643
Bates, 2001, Mortality and costs of acute renal failure associated with amphotericin B therapy, Clin Infect Dis, 32, 686, 10.1086/319211
Pfaller, 2010, Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods, Drug Resist Updat, 13, 180, 10.1016/j.drup.2010.09.002
Pfaller, 2011, Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria, Diagn Microbiol Infect Dis, 70, 330, 10.1016/j.diagmicrobio.2011.03.002
Pfaller, 2008, In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance, J Clin Microbiol, 46, 150, 10.1128/JCM.01901-07
Pfaller, 2010, Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp, J Clin Microbiol, 48, 52, 10.1128/JCM.01590-09
Pfaller, 2011, Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida, J Clin Microbiol, 49, 3800, 10.1128/JCM.05047-11
Pfaller, 2011, Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009), Diagn Microbiol Infect Dis, 69, 45, 10.1016/j.diagmicrobio.2010.08.013
Bruggemann, 2009, Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents, Clin Infect Dis, 48, 1441, 10.1086/598327
Goldman, 2005, A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40, Clin Infect Dis, 41, 1473, 10.1086/497373
Sobel, 2001, Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole, Am J Obstet Gynecol, 185, 363, 10.1067/mob.2001.115116
Zimmermann, 1994, Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole, Eur J Clin Pharmacol, 46, 147, 10.1007/BF00199879
Thaler, 1995, Fluconazole penetration in cerebral parenchyma in humans at steady state, Antimicrob Agents Chemother, 39, 1154, 10.1128/AAC.39.5.1154
Tod, 1997, Intravitreous penetration of fluconazole during endophthalmitis, Clin Microbiol Infect, 3, 379A, 10.1111/j.1469-0691.1997.tb00269.x
Tucker, 1988, Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis, Antimicrob Agents Chemother, 32, 369, 10.1128/AAC.32.3.369
Dodds Ashley, 2006, Pharmacology of systemic antifungal agents, Clin Infect Dis, 43, S28, 10.1086/504492
Eichel, 1996, Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis [in German], Mycoses, 39, 102, 10.1111/j.1439-0507.1996.tb00514.x
Lange, 1997, Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers, J Clin Pharmacol, 37, 535, 10.1002/j.1552-4604.1997.tb04332.x
Van Peer, 1989, The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects, Eur J Clin Pharmacol, 36, 423, 10.1007/BF00558308
Ally, 2001, A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients, Clin Infect Dis, 33, 1447, 10.1086/322653
Kethireddy, 2007, CNS pharmacokinetics of antifungal agents, Expert Opin Drug Metab Toxicol, 3, 573, 10.1517/17425255.3.4.573
Purkins, 2003, The pharmacokinetics and safety of intravenous voriconazole—a novel wide-spectrum antifungal agent, Br J Clin Pharmacol, 56, 2, 10.1046/j.1365-2125.2003.01992.x
Schwartz, 2005, Improved outcome in central nervous system aspergillosis, using voriconazole treatment, Blood, 106, 2641, 10.1182/blood-2005-02-0733
Purkins, 2003, Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole, Br J Clin Pharmacol, 56, 51, 10.1046/j.1365-2125.2003.01999.x
Purkins, 2003, Effect of food on the pharmacokinetics of multiple-dose oral voriconazole, Br J Clin Pharmacol, 56, 17, 10.1046/j.1365-2125.2003.01994.x
Neofytos, 2012, Administration of voriconazole in patients with renal dysfunction, Clin Infect Dis, 54, 913, 10.1093/cid/cir969
Oude Lashof, 2012, Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia, Antimicrob Agents Chemother, 56, 3133, 10.1128/AAC.05841-11
Alffenaar, 2009, High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?, Br J Clin Pharmacol, 67, 262, 10.1111/j.1365-2125.2008.03315.x
Ikeda, 2004, Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status, Clin Pharmacol Ther, 75, 587, 10.1016/j.clpt.2004.02.002
Eiden, 2007, Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database, Ann Pharmacother, 41, 755, 10.1345/aph.1H671
Hoffman, 2002, Review of the safety and efficacy of voriconazole, Expert Opin Investig Drugs, 11, 409, 10.1517/13543784.11.3.409
Malani, 2015, Voriconazole: how to use this antifungal agent and what to expect, Semin Respir Crit Care Med, 36, 786, 10.1055/s-0035-1562903
Pfaller, 2004, In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program, Diagn Microbiol Infect Dis, 48, 201, 10.1016/j.diagmicrobio.2003.09.008
Krishna, 2012, Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension, Antimicrob Agents Chemother, 56, 4196, 10.1128/AAC.00222-12
Krishna, 2012, A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers, J Antimicrob Chemother, 67, 2725, 10.1093/jac/dks268
Courtney, 2004, Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults, Br J Clin Pharmacol, 57, 218, 10.1046/j.1365-2125.2003.01977.x
Ezzet, 2005, Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations, Clin Pharmacokinet, 44, 211, 10.2165/00003088-200544020-00006
Alffenaar, 2009, Omeprazole significantly reduces posaconazole serum trough level, Clin Infect Dis, 48, 839, 10.1086/597110
Dannaoui, 2012, Candida spp. with acquired echinocandin resistance, France, 2004–2010, Emerg Infect Dis, 18, 86, 10.3201/eid1801.110556
Shields, 2013, Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and echinocandin resistance, Antimicrob Agents Chemother, 57, 6361, 10.1128/AAC.01451-13
de Wet, 2004, A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients, Clin Infect Dis, 39, 842, 10.1086/423377
Villanueva, 2001, A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis, Clin Infect Dis, 33, 1529, 10.1086/323401
Malani, 2007, Candida urinary tract infections: treatment options, Expert Rev Anti Infect Ther, 5, 277, 10.1586/14787210.5.2.277
Francis, 1992, Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy, Clin Infect Dis, 15, 1003, 10.1093/clind/15.6.1003
Pasqualotto, 2007, Flucytosine therapeutic monitoring: 15 years experience from the UK, J Antimicrob Chemother, 59, 791, 10.1093/jac/dkl550
Barchiesi, 2000, Primary resistance to flucytosine among clinical isolates of Candida spp, J Antimicrob Chemother, 45, 408, 10.1093/jac/45.3.408
Fisher, 2011, Candida urinary tract infections—treatment, Clin Infect Dis, 52, S457, 10.1093/cid/cir112
Lestner, 2013, Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective, Br J Clin Pharmacol, 75, 1381, 10.1111/bcp.12025
Starke, 1987, Pharmacokinetics of amphotericin B in infants and children, J Infect Dis, 155, 766, 10.1093/infdis/155.4.766
Koren, 1988, Pharmacokinetics and adverse effects of amphotericin B in infants and children, J Pediatr, 113, 559, 10.1016/S0022-3476(88)80653-X
Benson, 1989, Pharmacokinetics of amphotericin B in children, Antimicrob Agents Chemother, 33, 1989, 10.1128/AAC.33.11.1989
Walsh, 1997, Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis, Antimicrob Agents Chemother, 41, 1944, 10.1128/AAC.41.9.1944
Hong, 2006, Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases, Antimicrob Agents Chemother, 50, 935, 10.1128/AAC.50.3.935-942.2006
Baley, 1990, Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates, J Pediatr, 116, 791, 10.1016/S0022-3476(05)82674-5
Lee, 1992, Safety and pharmacokinetics of fluconazole in children with neoplastic diseases, J Pediatr, 120, 987, 10.1016/S0022-3476(05)81975-4
Saxen, 1993, Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life, Clin Pharmacol Ther, 54, 269, 10.1038/clpt.1993.147
Seay, 1995, Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases, Pharmacotherapy, 15, 52, 10.1002/j.1875-9114.1995.tb04331.x
Wade, 2008, Population pharmacokinetics of fluconazole in young infants, Antimicrob Agents Chemother, 52, 4043, 10.1128/AAC.00569-08
Walsh, 2004, Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration, Antimicrob Agents Chemother, 48, 2166, 10.1128/AAC.48.6.2166-2172.2004
Driscoll, 2011, Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults, Antimicrob Agents Chemother, 55, 5770, 10.1128/AAC.00531-11
Driscoll, 2011, Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults, Antimicrob Agents Chemother, 55, 5780, 10.1128/AAC.05010-11
Hope, 2010, Population pharmacokinetics of micafungin in neonates and young infants, Antimicrob Agents Chemother, 54, 2633, 10.1128/AAC.01679-09
Benjamin, 2006, Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections, Antimicrob Agents Chemother, 50, 632, 10.1128/AAC.50.2.632-638.2006
Dowell, 2004, Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal, J Clin Pharmacol, 44, 590, 10.1177/0091270004265644
Livermore, 2013, Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection, Antimicrob Agents Chemother, 57, 281, 10.1128/AAC.01387-12
Moudgal, 2003, Antifungal drugs in pregnancy: a review, Expert Opin Drug Saf, 2, 475, 10.1517/14740338.2.5.475
Andes, 2009, Antifungal therapeutic drug monitoring: established and emerging indications, Antimicrob Agents Chemother, 53, 24, 10.1128/AAC.00705-08
Johnson, 2003, Voriconazole: a new triazole antifungal agent, Clin Infect Dis, 36, 630, 10.1086/367933
Neely, 2010, Voriconazole pharmacokinetics and pharmacodynamics in children, Clin Infect Dis, 50, 27, 10.1086/648679
Pascual, 2008, Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clin Infect Dis, 46, 201, 10.1086/524669
Smith, 2006, Voriconazole therapeutic drug monitoring, Antimicrob Agents Chemother, 50, 1570, 10.1128/AAC.50.4.1570-1572.2006
Vermes, 2000, Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions, J Antimicrob Chemother, 46, 171, 10.1093/jac/46.2.171
Clinical and Laboratory Standards Institute, Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd informational supplement 2008
Pfaller, 2012, Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution, J Clin Microbiol, 50, 2040, 10.1128/JCM.00248-12
Pfaller, 2011, Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria, Drug Resist Updat, 14, 164, 10.1016/j.drup.2011.01.004
Pfaller, 2011, Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution, J Clin Microbiol, 49, 630, 10.1128/JCM.02161-10
Pfaller, 2006, Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing, Clin Microbiol Rev, 19, 435, 10.1128/CMR.19.2.435-447.2006
Pfaller, 2012, Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata, J Clin Microbiol, 50, 1199, 10.1128/JCM.06112-11
Pfaller, 2010, Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008–2009), Diagn Microbiol Infect Dis, 68, 278, 10.1016/j.diagmicrobio.2010.06.015
Ben-Ami, 2012, Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection, Antimicrob Agents Chemother, 56, 2518, 10.1128/AAC.05947-11
Oxman, 2010, Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?, J Antimicrob Chemother, 65, 1460, 10.1093/jac/dkq136
Leroy, 2009, Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006), Crit Care Med, 37, 1612, 10.1097/CCM.0b013e31819efac0
Pfeiffer, 2011, Quantitation of Candida CFU in initial positive blood cultures, J Clin Microbiol, 49, 2879, 10.1128/JCM.00609-11
Telenti, 1991, Quantitative blood cultures in candidemia, Mayo Clin Proc, 66, 1120, 10.1016/S0025-6196(12)65791-7
Nguyen, 2012, Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis, Clin Infect Dis, 54, 1240, 10.1093/cid/cis200
Schell, 2012, Evaluation of a digital microfluidic real-time PCR platform to detect DNA of Candida albicans in blood, Eur J Clin Microbiol Infect Dis, 31, 2237, 10.1007/s10096-012-1561-6
Avni, 2011, PCR diagnosis of invasive candidiasis: systematic review and meta-analysis, J Clin Microbiol, 49, 665, 10.1128/JCM.01602-10
McMullan, 2008, A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults, Clin Infect Dis, 46, 890, 10.1086/528690
Ness, 1989, Candida antigen latex test for detection of invasive candidiasis in immunocompromised patients, J Infect Dis, 159, 495, 10.1093/infdis/159.3.495
Thaler, 1988, Hepatic candidiasis in cancer patients: the evolving picture of the syndrome, Ann Intern Med, 108, 88, 10.7326/0003-4819-108-1-88
Ellepola, 2005, Laboratory diagnosis of invasive candidiasis, J Microbiol, 43, 65
Clancy, 2008, Immunoglobulin G responses to a panel of Candida albicans antigens as accurate and early markers for the presence of systemic candidiasis, J Clin Microbiol, 46, 1647, 10.1128/JCM.02018-07
Mikulska, 2010, The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia, Crit Care, 14, R222, 10.1186/cc9365
Yera, 2001, Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis, Eur J Clin Microbiol Infect Dis, 20, 864, 10.1007/s100960100629
Prella, 2005, Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies, Diagn Microbiol Infect Dis, 51, 95, 10.1016/j.diagmicrobio.2004.08.015
Tissot, 2013, Beta-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis, Am J Respir Crit Care Med, 188, 1100, 10.1164/rccm.201211-2069OC
Karageorgopoulos, 2011, Beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis, Clin Infect Dis, 52, 750, 10.1093/cid/ciq206
Lu, 2011, Diagnosis of invasive fungal disease using serum (1-->3)-beta-D-glucan: a bivariate meta-analysis, Intern Med, 50, 2783, 10.2169/internalmedicine.50.6175
Onishi, 2012, Diagnostic accuracy of serum 1,3-beta-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis, J Clin Microbiol, 50, 7, 10.1128/JCM.05267-11
Jaijakul, 2012, (1,3)-beta-D-glucan as a prognostic marker of treatment response in invasive candidiasis, Clin Infect Dis, 55, 521, 10.1093/cid/cis456
Wheat, 2009, Approach to the diagnosis of invasive aspergillosis and candidiasis, Clin Chest Med, 30, 367, 10.1016/j.ccm.2009.02.012
Hachem, 2009, Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients, J Clin Microbiol, 47, 129, 10.1128/JCM.00506-08
Ellis, 2008, Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever, J Med Microbiol, 57, 287, 10.1099/jmm.0.47479-0
Pickering, 2005, Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections, J Clin Microbiol, 43, 5957, 10.1128/JCM.43.12.5957-5962.2005
Kato, 2001, Elevation of blood (1-->3)-beta-D-glucan concentrations in hemodialysis patients, Nephron, 89, 15, 10.1159/000046037
Usami, 2002, Positive (1-->3)-beta-D-glucan in blood components and release of (1-->3)-beta-D-glucan from depth-type membrane filters for blood processing, Transfusion, 42, 1189, 10.1046/j.1537-2995.2002.00162.x
Mennink-Kersten, 2006, 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid, N Engl J Med, 354, 2834, 10.1056/NEJMc053340
Alexander, 2010, The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation, J Clin Microbiol, 48, 4083, 10.1128/JCM.01183-10
Mikulska, 2013, (1–3)-beta-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections, Clin Infect Dis, 56, 1511, 10.1093/cid/cit073
Litvintseva, 2014, Utility of (1–3)-beta-D-glucan testing for diagnostics and monitoring response to treatment during the multistate outbreak of fungal meningitis and other infections, Clin Infect Dis, 58, 622, 10.1093/cid/cit808
Petraitiene, 2008, Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis, Antimicrob Agents Chemother, 52, 4121, 10.1128/AAC.00674-08
Theel, 2013, Detection of (1, 3)-beta-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts, Mycopathologia, 175, 33, 10.1007/s11046-012-9579-y
Jeragh, 2007, Candida lusitaniae arthritis in an intravenous drug user, Mycoses, 50, 430, 10.1111/j.1439-0507.2007.01394.x
Mularoni, 2010, High levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease, Clin Vaccine Immunol, 17, 882, 10.1128/CVI.00038-10
Smith, 2007, Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting, Clin Vaccine Immunol, 14, 924, 10.1128/CVI.00025-07
Mylonakis, 2015, T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial, Clin Infect Dis, 60, 892, 10.1093/cid/ciu959
Lucignano, 2011, Multiplex PCR allows rapid and accurate diagnosis of bloodstream infections in newborns and children with suspected sepsis, J Clin Microbiol, 49, 2252, 10.1128/JCM.02460-10
Schuster, 2013, Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study, J Infect, 66, 278, 10.1016/j.jinf.2012.11.002
Dupont, 2009, Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B, Crit Care, 13, R159, 10.1186/cc8117
Horn, 2009, Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry, Clin Infect Dis, 48, 1695, 10.1086/599039
Labelle, 2008, Treatment-related risk factors for hospital mortality in Candida bloodstream infections, Crit Care Med, 36, 2967, 10.1097/CCM.0b013e31818b3477
Kohno, 2013, A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis, Eur J Clin Microbiol Infect Dis, 32, 387, 10.1007/s10096-012-1754-z
Kett, 2011, Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study, Crit Care Med, 39, 665, 10.1097/CCM.0b013e318206c1ca
Mootsikapun, 2013, Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label phase III trial, BMC Infect Dis, 13, 219, 10.1186/1471-2334-13-219
Walsh, 2002, Echinocandins—an advance in the primary treatment of invasive candidiasis, N Engl J Med, 347, 2070, 10.1056/NEJMe020142
Bennett, 2006, Echinocandins for candidemia in adults without neutropenia, N Engl J Med, 355, 1154, 10.1056/NEJMct060052
Bassetti, 2013, Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain, J Clin Microbiol, 51, 4167, 10.1128/JCM.01998-13
Orasch, 2014, Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland, Clin Microbiol Infect, 20, 698, 10.1111/1469-0691.12440
Fernandez-Ruiz, 2014, Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis, Clin Infect Dis, 58, 1413, 10.1093/cid/ciu158
Espinel-Ingroff, 2005, International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole, J Clin Microbiol, 43, 3884, 10.1128/JCM.43.8.3884-3889.2005
Pfaller, 2007, Epidemiology of invasive candidiasis: a persistent public health problem, Clin Microbiol Rev, 20, 133, 10.1128/CMR.00029-06
Espinel-Ingroff, 2014, Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole, Antimicrob Agents Chemother, 58, 2006, 10.1128/AAC.02615-13
Pfaller, 2013, In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds, J Clin Microbiol, 51, 2608, 10.1128/JCM.00863-13
Shields, 2013, Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure, Antimicrob Agents Chemother, 57, 3528, 10.1128/AAC.00136-13
Beyda, 2012, Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches, Ann Pharmacother, 46, 1086, 10.1345/aph.1R020
Vinikoor, 2013, Do all candidemic patients need an ophthalmic examination?, Int J Infect Dis, 17, e146, 10.1016/j.ijid.2012.12.014
Wagner, 2011, Prospective study on central venous line associated bloodstream infections, Arch Dis Child, 96, 827, 10.1136/adc.2010.208595
Chow, 2008, Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit, Clin Infect Dis, 46, 1206, 10.1086/529435
Chow, 2008, Risk factors for albicans and non-albicans candidemia in the intensive care unit, Crit Care Med, 36, 1993, 10.1097/CCM.0b013e31816fc4cd
Advani, 2011, Central line-associated bloodstream infection in hospitalized children with peripherally inserted central venous catheters: extending risk analyses outside the intensive care unit, Clin Infect Dis, 52, 1108, 10.1093/cid/cir145
Ruiz, 2013, Candidemia by species of the Candida parapsilosis complex in children's hospital: prevalence, biofilm production and antifungal susceptibility, Mycopathologia, 175, 231, 10.1007/s11046-013-9616-5
Tumbarello, 2012, Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital, PLoS One, 7, e33705, 10.1371/journal.pone.0033705
Nucci, 2010, Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials, Clin Infect Dis, 51, 295, 10.1086/653935
Velasco, 2011, Factors prompting early central venous catheter removal from cancer patients with candidaemia, Scand J Infect Dis, 43, 27, 10.3109/00365548.2010.524657
Lai, 2012, Impact of Port-A-Cath device management in cancer patients with candidaemia, J Hosp Infect, 82, 281, 10.1016/j.jhin.2012.08.007
Garnacho-Montero, 2013, Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections, J Antimicrob Chemother, 68, 206, 10.1093/jac/dks347
Rex, 1995, Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group, Clin Infect Dis, 21, 994, 10.1093/clinids/21.4.994
Nguyen, 1995, Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study, Arch Intern Med, 155, 2429, 10.1001/archinte.1995.00430220087009
Luzzati, 2000, Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital, Eur J Clin Microbiol Infect Dis, 19, 602, 10.1007/s100960000325
Liu, 2009, Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome, J Infect, 58, 154, 10.1016/j.jinf.2008.12.008
Karlowicz, 2000, Should central venous catheters be removed as soon as candidemia is detected in neonates?, Pediatrics, 106, E63, 10.1542/peds.106.5.e63
Klatte, 2013, Incidence, classification, and risk stratification for Candida central line-associated bloodstream infections in pediatric patients at a tertiary care children's hospital, 2000–2010, Infect Control Hosp Epidemiol, 34, 1266, 10.1086/673988
Devrim, 2014, A single center's experience with Candida parapsilosis related long-term central venous access device infections: the port removal decision and its outcomes, Pediatr Hematol Oncol, 31, 435, 10.3109/08880018.2013.862587
Nucci, 2001, Revisiting the source of candidemia: skin or gut?, Clin Infect Dis, 33, 1959, 10.1086/323759
Anaissie, 1998, Predictors of adverse outcome in cancer patients with candidemia, Am J Med, 104, 238, 10.1016/S0002-9343(98)00030-8
Nucci, 1998, Risk factors for death among cancer patients with fungemia, Clin Infect Dis, 27, 107, 10.1086/514609
Velasco, 2008, A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia, Eur J Clin Microbiol Infect Dis, 27, 1071, 10.1007/s10096-008-0546-y
Kanji, 2013, Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials, Leuk Lymphoma, 54, 1479, 10.3109/10428194.2012.745073
Cornely, 2011, Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease, Mycoses, 54, e838, 10.1111/j.1439-0507.2011.02045.x
Ullmann, 2012, ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT), Clin Microbiol Infect, 18, 53, 10.1111/1469-0691.12041
Betts, 2006, Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients, Cancer, 106, 466, 10.1002/cncr.21615
Walsh, 1999, Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group, N Engl J Med, 340, 764, 10.1056/NEJM199903113401004
Walsh, 2004, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med, 351, 1391, 10.1056/NEJMoa040446
Walsh, 2002, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever, N Engl J Med, 346, 225, 10.1056/NEJM200201243460403
Horn, 2010, Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials, Eur J Clin Microbiol Infect Dis, 29, 223, 10.1007/s10096-009-0843-0
Price, 2000, Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation, Blood, 95, 3302, 10.1182/blood.V95.11.3302
Grigull, 2006, G-CSF mobilised granulocyte transfusions in 32 paediatric patients with neutropenic sepsis, Support Care Cancer, 14, 910, 10.1007/s00520-006-0041-x
Safdar, 2004, Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections, Cancer, 101, 2859, 10.1002/cncr.20710
Seidel, 2008, Randomized phase III study of granulocyte transfusions in neutropenic patients, Bone Marrow Transplant, 42, 679, 10.1038/bmt.2008.237
Kontoyiannis, 2000, Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis, Infect Dis Clin North Am, 14, 721, 10.1016/S0891-5520(05)70128-8
Masood, 2005, Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment, Leuk Res, 29, 493, 10.1016/j.leukres.2004.10.003
Rammaert, 2012, New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis, Mycoses, 55, e74, 10.1111/j.1439-0507.2012.02182.x
Anttila, 1996, Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia, Eur J Haematol, 56, 82, 10.1111/j.1600-0609.1996.tb00300.x
Hot, 2011, Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections, Clin Microbiol Infect, 17, 409, 10.1111/j.1469-0691.2010.03301.x
Anttila, 1997, Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications, Clin Infect Dis, 24, 375, 10.1093/clinids/24.3.375
De Castro, 2012, Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000–2007, Clin Microbiol Infect, 18, E185, 10.1111/j.1469-0691.2012.03819.x
Gokhale, 1993, Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report, J Cancer Res Clin Oncol, 119, 569, 10.1007/BF01372718
Sallah, 1999, Amphotericin B lipid complex for the treatment of patients with acute leukemia and hepatosplenic candidiasis, Leuk Res, 23, 995, 10.1016/S0145-2126(99)00129-0
Kauffman, 1991, Hepatosplenic candidiasis: successful treatment with fluconazole, Am J Med, 91, 137, 10.1016/0002-9343(91)90005-I
Anaissie, 1991, Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy, Am J Med, 91, 142, 10.1016/0002-9343(91)90006-J
Cornely, 2007, Caspofungin for the treatment of less common forms of invasive candidiasis, J Antimicrob Chemother, 60, 363, 10.1093/jac/dkm169
Ostrosky-Zeichner, 2003, Voriconazole salvage treatment of invasive candidiasis, Eur J Clin Microbiol Infect Dis, 22, 651, 10.1007/s10096-003-1014-3
Lehrnbecher, 2010, Posaconazole salvage treatment in paediatric patients: a multicentre survey, Eur J Clin Microbiol Infect Dis, 29, 1043, 10.1007/s10096-010-0957-4
Poon, 2009, Successful intensive chemotherapy followed by autologous hematopoietic cell transplantation in a patient with acute myeloid leukemia and hepatosplenic candidiasis: case report and review of literature, Transpl Infect Dis, 11, 160, 10.1111/j.1399-3062.2009.00363.x
Legrand, 2008, Adjuvant corticosteroid therapy for chronic disseminated candidiasis, Clin Infect Dis, 46, 696, 10.1086/527390
Chaussade, 2012, Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review, J Antimicrob Chemother, 67, 1493, 10.1093/jac/dks044
Eggimann, 2010, Early antifungal intervention strategies in ICU patients, Curr Opin Crit Care, 16, 465, 10.1097/MCC.0b013e32833e0487
Zaoutis, 2005, The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis, Clin Infect Dis, 41, 1232, 10.1086/496922
Marriott, 2009, Determinants of mortality in non-neutropenic ICU patients with candidaemia, Crit Care, 13, R115, 10.1186/cc7964
Pittet, 1994, Candida colonization and subsequent infections in critically ill surgical patients, Ann Surg, 220, 751, 10.1097/00000658-199412000-00008
Blumberg, 2001, Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey, Clin Infect Dis, 33, 177, 10.1086/321811
Troughton, 2010, Prior colonisation with Candida species fails to guide empirical therapy for candidaemia in critically ill adults, J Infect, 61, 403, 10.1016/j.jinf.2010.08.013
Leon, 2006, A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization, Crit Care Med, 34, 730, 10.1097/01.CCM.0000202208.37364.7D
Michalopoulos, 2003, Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients, Chest, 124, 2244, 10.1378/chest.124.6.2244
Ostrosky-Zeichner, 2011, Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit, Mycoses, 54, 46, 10.1111/j.1439-0507.2009.01756.x
Dupont, 2002, Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients, Arch Surg, 137, 1341, 10.1001/archsurg.137.12.1341
Montravers, 2006, Candida as a risk factor for mortality in peritonitis, Crit Care Med, 34, 646, 10.1097/01.CCM.0000201889.39443.D2
Presterl, 2009, Invasive fungal infections and (1,3)-beta-D-glucan serum concentrations in long-term intensive care patients, Int J Infect Dis, 13, 707, 10.1016/j.ijid.2008.10.013
Mohr, 2011, Prospective survey of (1-->3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting, J Clin Microbiol, 49, 58, 10.1128/JCM.01240-10
Koo, 2009, Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease, Clin Infect Dis, 49, 1650, 10.1086/647942
Posteraro, 2011, Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1-->3)-beta-D-glucan assay, Candida score, and colonization index, Crit Care, 15, R249, 10.1186/cc10507
Ostrosky-Zeichner, 2014, MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting, Clin Infect Dis, 58, 1219, 10.1093/cid/ciu074
Digby, 2003, Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients, Clin Diagn Lab Immunol, 10, 882, 10.1128/CDLI.10.5.882-885.2003
Hanson, 2012, Beta-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study, PLoS One, 7, e42282, 10.1371/journal.pone.0042282
Obayashi, 2008, Reappraisal of the serum (1-->3)-beta-D-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years, Clin Infect Dis, 46, 1864, 10.1086/588295
Arendrup, 2010, Detection of candidaemia in patients with and without underlying haematological disease, Clin Microbiol Infect, 16, 855, 10.1111/j.1469-0691.2009.02931.x
Parkins, 2007, Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections, J Antimicrob Chemother, 60, 613, 10.1093/jac/dkm212
Piarroux, 2004, Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients, Crit Care Med, 32, 2443, 10.1097/01.CCM.0000147726.62304.7F
Shan, 2006, Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery, World J Surg, 30, 119, 10.1007/s00268-005-7807-z
Schuster, 2008, Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial, Ann Intern Med, 149, 83, 10.7326/0003-4819-149-2-200807150-00004
Ostrosky-Zeichner, 2012, Invasive mycoses: diagnostic challenges, Am J Med, 125, S14, 10.1016/j.amjmed.2011.10.008
Fagan, 2013, Incidence trends in pathogen-specific central line-associated bloodstream infections in US intensive care units, 1990–2010, Infect Control Hosp Epidemiol, 34, 893, 10.1086/671724
Ostrosky-Zeichner, 2004, Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit?, Crit Care Med, 32, 2552, 10.1097/01.CCM.0000148226.95597.7E
Garbino, 2002, Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination, Intensive Care Med, 28, 1708, 10.1007/s00134-002-1540-y
Pelz, 2001, Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients, Ann Surg, 233, 542, 10.1097/00000658-200104000-00010
Eggimann, 1999, Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients, Crit Care Med, 27, 1066, 10.1097/00003246-199906000-00019
Senn, 2009, Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients, Intensive Care Med, 35, 903, 10.1007/s00134-009-1405-8
Playford, 2006, Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials, J Antimicrob Chemother, 57, 628, 10.1093/jac/dki491
Shorr, 2005, Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis, Crit Care Med, 33, 1928, 10.1097/01.CCM.0000178352.14703.49
Vardakas, 2006, Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials, Crit Care Med, 34, 1216, 10.1097/01.CCM.0000208357.05675.C3
Cruciani, 2005, Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis, Intensive Care Med, 31, 1479, 10.1007/s00134-005-2794-y
Playford, 2001, Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients, Cochrane Database Syst Rev
Zaoutis, 2010, Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention, Clin Infect Dis, 51, e38, 10.1086/655698
Huang, 2013, Targeted versus universal decolonization to prevent ICU infection, N Engl J Med, 368, 2255, 10.1056/NEJMoa1207290
Climo, 2013, Effect of daily chlorhexidine bathing on hospital-acquired infection, N Engl J Med, 368, 533, 10.1056/NEJMoa1113849
Montecalvo, 2012, Chlorhexidine bathing to reduce central venous catheter-associated bloodstream infection: impact and sustainability, Am J Med, 125, 505, 10.1016/j.amjmed.2011.10.032
O'Horo, 2012, The efficacy of daily bathing with chlorhexidine for reducing healthcare-associated bloodstream infections: a meta-analysis, Infect Control Hosp Epidemiol, 33, 257, 10.1086/664496
Hocevar, 2012, Device-associated infections among neonatal intensive care unit patients: incidence and associated pathogens reported to the National Healthcare Safety Network, 2006–2008, Infect Control Hosp Epidemiol, 33, 1200, 10.1086/668425
Aliaga, 2014, Changes in the incidence of candidiasis in neonatal intensive care units, Pediatrics, 133, 236, 10.1542/peds.2013-0671
Fisher, 2014, Decreasing rates of invasive candidiasis in pediatric hospitals across the United States, Clin Infect Dis, 58, 74, 10.1093/cid/cit679
Chitnis, 2012, Trends in Candida central line-associated bloodstream infections among NICUs, 1999–2009, Pediatrics, 130, e46, 10.1542/peds.2011-3620
Benjamin, 2006, Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months, Pediatrics, 117, 84, 10.1542/peds.2004-2292
Zaoutis, 2007, Outcomes attributable to neonatal candidiasis, Clin Infect Dis, 44, 1187, 10.1086/513196
Wynn, 2012, Outcomes following candiduria in extremely low birth weight infants, Clin Infect Dis, 54, 331, 10.1093/cid/cir800
Stoll, 2004, Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection, JAMA, 292, 2357, 10.1001/jama.292.19.2357
Smith, 2007, Excess costs of hospital care associated with neonatal candidemia, Pediatr Infect Dis J, 26, 197, 10.1097/01.inf.0000253973.89097.c0
Benjamin, 2010, Safety and pharmacokinetics of repeat-dose micafungin in young infants, Clin Pharmacol Ther, 87, 93, 10.1038/clpt.2009.200
Cohen-Wolkowiez, 2007, Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures, J Perinatol, 27, 97, 10.1038/sj.jp.7211628
Fernandez, 2000, Candidal meningitis in neonates: a 10-year review, Clin Infect Dis, 31, 458, 10.1086/313973
Steinbach, 2012, Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates, Pediatr Infect Dis J, 31, 1252, 10.1097/INF.0b013e3182737427
Benjamin, 2003, Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques, Pediatrics, 112, 634, 10.1542/peds.112.3.634
Driessen, 1996, Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial, Pediatr Infect Dis J, 15, 1107, 10.1097/00006454-199612000-00011
Linder, 2003, Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations, J Antimicrob Chemother, 52, 663, 10.1093/jac/dkg419
Ascher, 2012, Antifungal therapy and outcomes in infants with invasive Candida infections, Pediatr Infect Dis J, 31, 439, 10.1097/INF.0b013e3182467a72
Piper, 2011, Fluconazole loading dose pharmacokinetics and safety in infants, Pediatr Infect Dis J, 30, 375, 10.1097/INF.0b013e318202cbb3
Odio, 2004, Caspofungin therapy of neonates with invasive candidiasis, Pediatr Infect Dis J, 23, 1093, 10.1097/01.inf.0000145408.51526.0a
Saez-Llorens, 2009, Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age, Antimicrob Agents Chemother, 53, 869, 10.1128/AAC.00868-08
Heresi, 2006, The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants, Pediatr Infect Dis J, 25, 1110, 10.1097/01.inf.0000245103.07614.e1
Hope, 2008, The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates, J Infect Dis, 197, 163, 10.1086/524063
Smith, 2009, Pharmacokinetics of an elevated dosage of micafungin in premature neonates, Pediatr Infect Dis J, 28, 412, 10.1097/INF.0b013e3181910e2d
Groll, 2001, Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling, Antimicrob Agents Chemother, 45, 2845, 10.1128/AAC.45.10.2845-2855.2001
Warn, 2012, Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach, Antimicrob Agents Chemother, 56, 708, 10.1128/AAC.05826-11
Manzoni, 2007, A multicenter, randomized trial of prophylactic fluconazole in preterm neonates, N Engl J Med, 356, 2483, 10.1056/NEJMoa065733
Manzoni, 2006, Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study, Pediatrics, 117, e22, 10.1542/peds.2004-2227
Kaufman, 2001, Fluconazole prophylaxis against fungal colonization and infection in preterm infants, N Engl J Med, 345, 1660, 10.1056/NEJMoa010494
Violaris, 2010, Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants, Am J Perinatol, 27, 73, 10.1055/s-0029-1224871
Weitkamp, 2008, Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure, J Perinatol, 28, 405, 10.1038/sj.jp.7211914
Uko, 2006, Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants, Pediatrics, 117, 1243, 10.1542/peds.2005-1969
Rolnitsky, 2012, Targeted fluconazole prophylaxis for high-risk very low birth weight infants, Eur J Pediatr, 171, 1481, 10.1007/s00431-012-1760-2
Kicklighter, 2001, Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant, Pediatrics, 107, 293, 10.1542/peds.107.2.293
Martin, 2012, Impact of ‘targeted’ fluconazole prophylaxis for preterm neonates: efficacy of a highly selective approach?, J Perinatol, 32, 21, 10.1038/jp.2011.27
Healy, 2008, Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species, Pediatrics, 121, 703, 10.1542/peds.2007-1130
Healy, 2005, Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit, J Pediatr, 147, 166, 10.1016/j.jpeds.2005.04.016
Ozturk, 2006, Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit, Mycoses, 49, 484, 10.1111/j.1439-0507.2006.01274.x
Sims, 1988, Prophylactic oral nystatin and fungal infections in very-low-birthweight infants, Am J Perinatol, 5, 33, 10.1055/s-2007-999649
Howell, 2009, Oral nystatin prophylaxis and neonatal fungal infections, Arch Dis Child Fetal Neonatal Ed, 94, F429, 10.1136/adc.2008.157123
Manzoni, 2012, Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial, Pediatrics, 129, 116, 10.1542/peds.2011-0279
Bassetti, 2013, A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts, Intensive Care Med, 39, 2092, 10.1007/s00134-013-3109-3
Sandven, 2002, Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations, Crit Care Med, 30, 541, 10.1097/00003246-200203000-00008
Lee, 2009, Effect of botulinum toxin type a on a rat surgical wound model, Clin Exp Otorhinolaryngol, 2, 20, 10.3342/ceo.2009.2.1.20
Vege, 2009, Outcomes of intra-abdominal fungal vs. bacterial infections in severe acute pancreatitis, Am J Gastroenterol, 104, 2065, 10.1038/ajg.2009.280
de Ruiter, 2009, The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis, Infection, 37, 522, 10.1007/s15010-009-8249-6
Roehrborn, 2001, The microbiology of postoperative peritonitis, Clin Infect Dis, 33, 1513, 10.1086/323333
Montravers, 2009, Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study, J Antimicrob Chemother, 63, 785, 10.1093/jac/dkp005
Masur, 1977, Pulmonary disease caused by Candida species, Am J Med, 63, 914, 10.1016/0002-9343(77)90546-0
Kontoyiannis, 2002, Pulmonary candidiasis in patients with cancer: an autopsy study, Clin Infect Dis, 34, 400, 10.1086/338404
Tamai, 2012, Fatal community-acquired primary Candida pneumonia in an alcoholic patient, Intern Med, 51, 3159, 10.2169/internalmedicine.51.8569
Pasqualotto, 2009, Candida and the paediatric lung, Paediatr Respir Rev, 10, 186, 10.1016/j.prrv.2009.09.001
Lewis, 2013, Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study, Mycoses, 56, 638, 10.1111/myc.12081
Sharma, 2005, Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings, Chest, 128, 1385, 10.1378/chest.128.3.1385
Meersseman, 2009, Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study, Intensive Care Med, 35, 1526, 10.1007/s00134-009-1482-8
Rello, 1998, The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients, Chest, 114, 146, 10.1378/chest.114.1.146
el-Ebiary, 1997, Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study, Am J Respir Crit Care Med, 156, 583, 10.1164/ajrccm.156.2.9612023
Wood, 2006, Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients, Intensive Care Med, 32, 599, 10.1007/s00134-005-0065-6
Williamson, 2011, The relationship between Candida species cultured from the respiratory tract and systemic inflammation in critically ill patients with ventilator-associated pneumonia, Can J Anaesth, 58, 275, 10.1007/s12630-010-9439-5
Delisle, 2008, The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients, J Crit Care, 23, 11, 10.1016/j.jcrc.2008.01.005
Roux, 2013, Airway fungal colonization compromises the immune system allowing bacterial pneumonia to prevail, Crit Care Med, 41, e191, 10.1097/CCM.0b013e31828a25d6
Mear, 2013, Candida albicans and Pseudomonas aeruginosa interactions: more than an opportunistic criminal association?, Med Mal Infect, 43, 146, 10.1016/j.medmal.2013.02.005
Hamet, 2012, Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia, Intensive Care Med, 38, 1272, 10.1007/s00134-012-2584-2
Card, 2012, Candidal endocarditis presenting with bilateral lower limb ischemia, Clin Lab Sci, 25, 130, 10.29074/ascls.25.3.130
Ellis, 2001, Fungal endocarditis: evidence in the world literature, 1965–1995, Clin Infect Dis, 32, 50, 10.1086/317550
Venditti, 1992, Fluconazole treatment of catheter-related right-sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis, Clin Infect Dis, 14, 422, 10.1093/clinids/14.2.422
Czwerwiec, 1993, Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis, Am J Med, 94, 545, 10.1016/0002-9343(93)90092-4
Nguyen, 1996, Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature, Clin Infect Dis, 22, 262, 10.1093/clinids/22.2.262
Lejko-Zupanc, 1997, A case of recurrent Candida parapsilosis prosthetic valve endocarditis: cure by medical treatment alone, J Infect, 35, 81, 10.1016/S0163-4453(97)91145-2
Melamed, 2000, Successful non-surgical treatment of Candida tropicalis endocarditis with liposomal amphotericin-B (AmBisome), Scand J Infect Dis, 32, 86, 10.1080/00365540050164281
Aaron, 2003, Successful medical treatment of Candida albicans in mechanical prosthetic valve endocarditis, Scand J Infect Dis, 35, 351, 10.1080/00365540310008357
Jimenez-Exposito, 2004, Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment, Clin Infect Dis, 39, e70, 10.1086/424018
Westling, 2005, Candida albicans tricuspid valve endocarditis in an intravenous drug addict: successful treatment with fluconazole, Scand J Infect Dis, 37, 310, 10.1080/00365540410021207-1
Rajendram, 2005, Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement, Clin Infect Dis, 40, e72, 10.1086/429322
Steinbach, 2005, A meta-analysis of medical versus surgical therapy for Candida endocarditis, J Infect, 51, 230, 10.1016/j.jinf.2004.10.016
Muehrcke, 1995, Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis, Ann Thorac Surg, 60, 538, 10.1016/0003-4975(95)00469-2
Mayayo, 1996, Fungal endocarditis in premature infants: case report and review, Clin Infect Dis, 22, 366, 10.1093/clinids/22.2.366
Levy, 2006, Candida endocarditis in neonates: report of five cases and review of the literature, Mycoses, 49, 43, 10.1111/j.1439-0507.2005.01183.x
Noyola, 2001, Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia, Clin Infect Dis, 32, 1018, 10.1086/319601
Smego, 2011, The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis, Medicine (Baltimore), 90, 237, 10.1097/MD.0b013e3182259d38
Rubinstein, 1974, Tissue penetration of amphotericin B in Candida endocarditis, Chest, 66, 376, 10.1378/chest.66.4.376
Kuhn, 2002, Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins, Antimicrob Agents Chemother, 46, 1773, 10.1128/AAC.46.6.1773-1780.2002
Mrowczynski, 2004, Caspofungin for Candida endocarditis, Pediatr Infect Dis J, 23, 376, 10.1097/00006454-200404000-00029
Moudgal, 2005, Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis, Antimicrob Agents Chemother, 49, 767, 10.1128/AAC.49.2.767-769.2005
Bacak, 2006, Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient—case report and review of literature, J Infect, 53, e11, 10.1016/j.jinf.2005.10.003
Lye, 2005, Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review, Eur J Clin Microbiol Infect Dis, 24, 753, 10.1007/s10096-005-0038-2
Lopez-Ciudad, 2006, Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole, BMC Infect Dis, 6, 73, 10.1186/1471-2334-6-73
Baddley, 2008, Candida infective endocarditis, Eur J Clin Microbiol Infect Dis, 27, 519, 10.1007/s10096-008-0466-x
Falcone, 2009, Candida infective endocarditis: report of 15 cases from a prospective multicenter study, Medicine (Baltimore), 88, 160, 10.1097/MD.0b013e3181a693f8
Talarmin, 2009, Candida endocarditis: role of new antifungal agents, Mycoses, 52, 60, 10.1111/j.1439-0507.2008.01533.x
De Rosa, 2012, Anidulafungin for Candida glabrata infective endocarditis, Antimicrob Agents Chemother, 56, 4552, 10.1128/AAC.00515-12
Lefort, 2012, Diagnosis, management and outcome of Candida endocarditis, Clin Microbiol Infect, 18, E99, 10.1111/j.1469-0691.2012.03764.x
Penk, 1999, Role of fluconazole in the long-term suppressive therapy of fungal infections in patients with artificial implants, Mycoses, 42, 91, 10.1111/j.1439-0507.1999.tb00021.x
Boland, 2011, Fungal prosthetic valve endocarditis: Mayo Clinic experience with a clinicopathological analysis, Mycoses, 54, 354, 10.1111/j.1439-0507.2010.01884.x
Joly, 1997, Pacemaker endocarditis due to Candida albicans: case report and review, Clin Infect Dis, 25, 1359, 10.1086/516125
Roger, 2000, Medical treatment of a pacemaker endocarditis due to Candida albicans and to Candida glabrata, J Infect, 41, 176, 10.1053/jinf.2000.0640
Tascini, 2013, Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature, Mycopathologia, 175, 129, 10.1007/s11046-012-9591-2
Brown, 2001, Implantable cardioverter-defibrillator endocarditis secondary to Candida albicans, Am J Med Sci, 322, 160, 10.1097/00000441-200109000-00010
Hindupur, 2005, Septic shock induced from an implantable cardioverter-defibrillator lead-associated Candida albicans vegetation, J Interv Card Electrophysiol, 14, 55, 10.1007/s10840-005-3246-x
Halawa, 2011, Candida endocarditis associated with cardiac rhythm management devices: review with current treatment guidelines, Mycoses, 54, e168, 10.1111/j.1439-0507.2010.01866.x
Bagdasarian, 2009, Fungemia associated with left ventricular assist device support, J Card Surg, 24, 763, 10.1111/j.1540-8191.2009.00919.x
Shoham, 2007, Candidemia in patients with ventricular assist devices, Clin Infect Dis, 44, e9, 10.1086/509640
Aslam, 2010, Risk factors and outcomes of fungal ventricular-assist device infections, Clin Infect Dis, 50, 664, 10.1086/650454
Cabrera, 2013, Infectious complications and outcomes in children supported with left ventricular assist devices, J Heart Lung Transplant, 32, 518, 10.1016/j.healun.2013.02.002
Friedland, 1996, Peripheral thrombophlebitis caused by Candida, Pediatr Infect Dis J, 15, 375, 10.1097/00006454-199604000-00018
Benoit, 1998, Management of candidal thrombophlebitis of the central veins: case report and review, Clin Infect Dis, 26, 393, 10.1086/516319
Block, 2009, Thrombolytic therapy for management of complicated catheter-related Candida albicans thrombophlebitis, Intern Med J, 39, 61, 10.1111/j.1445-5994.2008.01867.x
Pan, 2005, Septic Candida krusei thrombophlebitis of inferior vena cava with persistent fungemia successfully treated by new antifungal agents, Med Mycol, 43, 731, 10.1080/13693780500302593
Arias, 2004, Candida albicans osteomyelitis: case report and literature review, Int J Infect Dis, 8, 307, 10.1016/j.ijid.2003.12.006
Gamaletsou, 2012, Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970–2011), Clin Infect Dis, 55, 1338, 10.1093/cid/cis660
Slenker, 2012, Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature, Diagn Microbiol Infect Dis, 73, 89, 10.1016/j.diagmicrobio.2012.02.004
Neofytos, 2014, Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance(R) registry, Eur J Clin Microbiol Infect Dis, 33, 135, 10.1007/s10096-013-1939-0
Hendrickx, 2001, Candidal vertebral osteomyelitis: report of 6 patients, and a review, Clin Infect Dis, 32, 527, 10.1086/318714
Miller, 2001, Vertebral osteomyelitis due to Candida species: case report and literature review, Clin Infect Dis, 33, 523, 10.1086/322634
Kaldau, 2012, Bilateral polymicrobial osteomyelitis with Candida tropicalis and Candida krusei: a case report and an updated literature review, Int J Infect Dis, 16, e16, 10.1016/j.ijid.2011.10.001
Hennequin, 1996, Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature, Clin Infect Dis, 23, 176, 10.1093/clinids/23.1.176
Malani, 2002, Candida albicans sternal wound infections: a chronic and recurrent complication of median sternotomy, Clin Infect Dis, 35, 1316, 10.1086/344192
Sugar, 1990, Successful treatment of Candida osteomyelitis with fluconazole. A noncomparative study of two patients, Diagn Microbiol Infect Dis, 13, 517, 10.1016/0732-8893(90)90084-9
Dan, 1994, Failure of fluconazole therapy for sternal osteomyelitis due to Candida albicans, Clin Infect Dis, 18, 126, 10.1093/clinids/18.1.126
Petrikkos, 2001, Case report. Successful treatment of two cases of post-surgical sternal osteomyelitis, due to Candida krusei and Candida albicans, respectively, with high doses of triazoles (fluconazole, itraconazole), Mycoses, 44, 422, 10.1046/j.1439-0507.2001.00673.x
Schilling, 2008, Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy, Med Mycol, 46, 79, 10.1080/13693780701552996
Legout, 2006, Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient, Scand J Infect Dis, 38, 728, 10.1080/00365540500447192
Marra, 2001, Amphotericin B-loaded bone cement to treat osteomyelitis caused by Candida albicans, Can J Surg, 44, 383
Sealy, 2009, Delivery of antifungal agents using bioactive and nonbioactive bone cements, Ann Pharmacother, 43, 1606, 10.1345/aph.1M143
Clancy, 1997, Candidal mediastinitis: an emerging clinical entity, Clin Infect Dis, 25, 608, 10.1086/513770
Harris, 2000, Candidal arthritis in infants previously treated for systemic candidiasis during the newborn period: report of three cases, Pediatr Emerg Care, 16, 249, 10.1097/00006565-200008000-00008
Weigl, 2000, Candida arthritis in a premature infant treated successfully with oral fluconazole for six months, Ann Acad Med Singapore, 29, 253
Sim, 2005, Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin, Hong Kong Med J, 11, 120
Merrer, 2001, Candida albicans prosthetic arthritis treated with fluconazole alone, J Infect, 42, 208, 10.1053/jinf.2001.0819
Tunkel, 1993, Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature, Am J Med, 94, 100, 10.1016/0002-9343(93)90127-B
Dutronc, 2010, Candida prosthetic infections: case series and literature review, Scand J Infect Dis, 42, 890, 10.3109/00365548.2010.498023
Anagnostakos, 2012, Fungal periprosthetic hip and knee joint infections clinical experience with a 2-stage treatment protocol, J Arthroplasty, 27, 293, 10.1016/j.arth.2011.04.044
Ueng, 2013, What is the success of treatment of hip and knee candidal periprosthetic joint infection?, Clin Orthop Relat Res, 471, 3002, 10.1007/s11999-013-3007-6
Goss, 2007, Elution and mechanical properties of antifungal bone cement, J Arthroplasty, 22, 902, 10.1016/j.arth.2006.09.013
Binder, 2003, Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center, Medicine (Baltimore), 82, 97, 10.1097/00005792-200303000-00004
Lingappan, 2012, Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes, Am J Ophthalmol, 153, 162, 10.1016/j.ajo.2011.06.020
Khan, 2007, Candida endophthalmitis: focus on current and future antifungal treatment options, Pharmacotherapy, 27, 1711, 10.1592/phco.27.12.1711
Lamaris, 2008, Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases, Eur J Clin Microbiol Infect Dis, 27, 343, 10.1007/s10096-007-0443-9
Fierro, 2013, Ocular manifestations of candidemia in children, Pediatr Infect Dis J, 32, 84, 10.1097/INF.0b013e31826f547c
Sallam, 2012, Factors determining visual outcome in endogenous Candida endophthalmitis, Retina, 32, 1129, 10.1097/IAE.0b013e31822d3a34
Krishna, 2000, Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis?, Eye (Lond), 14, 30, 10.1038/eye.2000.7
Popovich, 2007, Compliance with Infectious Diseases Society of America guidelines for ophthalmologic evaluation of patients with candidemia, Infect Dis Clin Pract, 15, 254, 10.1097/IPC.0b013e318059b95f
Karmisholt, 2008, Candidaemia and risk of intraocular infection: a Danish hospital-based cohort study, Scand J Infect Dis, 40, 241, 10.1080/00365540701642120
Riddell, 2011, Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents, Clin Infect Dis, 52, 648, 10.1093/cid/ciq204
Eltoukhy, 2010, Antifungal distribution into cerebrospinal fluid, vitreous humor, bone, and other difficult sites, Curr Fungal Infect Rep, 4, 111, 10.1007/s12281-010-0016-8
Blennow, 2013, Duration of treatment for candidemia and risk for late-onset ocular candidiasis, Infection, 41, 129, 10.1007/s15010-012-0369-8
Essman, 1997, Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis, Ophthalmic Surg Lasers, 28, 185, 10.3928/1542-8877-19970301-03
Zhang, 2005, Treatment outcomes after pars plana vitrectomy for endogenous endophthalmitis, Retina, 25, 746, 10.1097/00006982-200509000-00010
Martinez-Vazquez, 1998, Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy, Clin Infect Dis, 27, 1130, 10.1086/514972
Dozier, 2011, Fungal eye disease at a tertiary care center: the utility of routine inpatient consultation, Ophthalmology, 118, 1671, 10.1016/j.ophtha.2011.01.038
Goldblum, 2002, Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model, Antimicrob Agents Chemother, 46, 3719, 10.1128/AAC.46.12.3719-3723.2002
Louie, 1999, Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans, Antimicrob Agents Chemother, 43, 2831, 10.1128/AAC.43.12.2831
Osthoff, 2006, Endogenous endophthalmitis with azole-resistant Candida albicans—case report and review of the literature, Infection, 34, 285, 10.1007/s15010-006-5119-3
O'Day, 1985, Intraocular penetration of systemically administered antifungal agents, Curr Eye Res, 4, 131, 10.3109/02713688508999978
Filler, 1991, Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits, Antimicrob Agents Chemother, 35, 288, 10.1128/AAC.35.2.288
Park, 1995, Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole, Antimicrob Agents Chemother, 39, 958, 10.1128/AAC.39.4.958
Akler, 1995, Use of fluconazole in the treatment of candidal endophthalmitis, Clin Infect Dis, 20, 657, 10.1093/clinids/20.3.657
Luttrull, 1995, Treatment of ocular fungal infections with oral fluconazole, Am J Ophthalmol, 119, 477, 10.1016/S0002-9394(14)71234-6
Breit, 2005, Management of endogenous fungal endophthalmitis with voriconazole and caspofungin, Am J Ophthalmol, 139, 135, 10.1016/j.ajo.2004.08.077
Hariprasad, 2004, Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans, Arch Ophthalmol, 122, 42, 10.1001/archopht.122.1.42
Hariprasad, 2008, Voriconazole in the treatment of fungal eye infections: a review of current literature, Br J Ophthalmol, 92, 871, 10.1136/bjo.2007.136515
Suzuki, 2008, Ocular distribution of intravenously administered micafungin in rabbits, J Infect Chemother, 14, 204, 10.1007/s10156-008-0612-5
Mochizuki, 2013, Intraocular penetration of intravenous micafungin in inflamed human eyes, Antimicrob Agents Chemother, 57, 4027, 10.1128/AAC.02300-12
Groll, 2001, Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits, Antimicrob Agents Chemother, 45, 3322, 10.1128/AAC.45.12.3322-3327.2001
Groll, 2001, Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits, Antimicrob Agents Chemother, 45, 596, 10.1128/AAC.45.2.596-600.2001
Goldblum, 2007, Ocular penetration of caspofungin in a rabbit uveitis model, Graefes Arch Clin Exp Ophthalmol, 245, 825, 10.1007/s00417-006-0460-x
Sarria, 2005, Candida glabrata endophthalmitis treated successfully with caspofungin, Clin Infect Dis, 40, e46, 10.1086/427753
Gauthier, 2005, Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis, Clin Infect Dis, 41, e27, 10.1086/431761
Cannon, 2003, Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model, Invest Ophthalmol Vis Sci, 44, 2112, 10.1167/iovs.02-1020
Tremblay, 1985, Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits, Invest Ophthalmol Vis Sci, 26, 711
Sen, 2006, Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series, Retina, 26, 935, 10.1097/01.iae.0000250011.68532.a2
Kernt, 2009, Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis, Retina, 29, 362, 10.1097/IAE.0b013e31818d4b9b
Wingard, 1989, Intraocular distribution of intravitreally administered amphotericin B in normal and vitrectomized eyes, Invest Ophthalmol Vis Sci, 30, 2184
Shen, 2007, Clearance of intravitreal voriconazole, Invest Ophthalmol Vis Sci, 48, 2238, 10.1167/iovs.06-1362
Shen, 2009, Vitrectomy for endogenous fungal endophthalmitis, Ocul Immunol Inflamm, 17, 148, 10.1080/09273940802689396
Sanchez-Portocarrero, 2000, The central nervous system and infection by Candida species, Diagn Microbiol Infect Dis, 37, 169, 10.1016/S0732-8893(00)00140-1
Chen, 2004, Clinical characteristics, treatment and prognostic factors of candidal meningitis in a teaching hospital in Taiwan, Scand J Infect Dis, 36, 124, 10.1080/00365540310017573
Nguyen, 1995, Meningitis caused by Candida species: an emerging problem in neurosurgical patients, Clin Infect Dis, 21, 323, 10.1093/clinids/21.2.323
O'Brien, 2011, Candida parapsilosis meningitis associated with Gliadel (BCNU) wafer implants, Br J Neurosurg, 25, 289, 10.3109/02688697.2010.534202
Casado, 1997, Candidal meningitis in HIV-infected patients: analysis of 14 cases, Clin Infect Dis, 25, 673, 10.1086/513746
Burgert, 1995, Candidal brain abscess associated with vascular invasion: a devastating complication of vascular catheter-related candidemia, Clin Infect Dis, 21, 202, 10.1093/clinids/21.1.202
Voice, 1994, Chronic candidal meningitis: an uncommon manifestation of candidiasis, Clin Infect Dis, 19, 60, 10.1093/clinids/19.1.60
Montero, 2000, Candida infection of cerebrospinal fluid shunt devices: report of two cases and review of the literature, Acta Neurochir (Wien), 142, 67, 10.1007/s007010050009
McCullers, 2000, Candidal meningitis in children with cancer, Clin Infect Dis, 31, 451, 10.1086/313987
Fennelly, 2013, Candida cerebral abscesses: a case report and review of the literature, Med Mycol, 51, 779, 10.3109/13693786.2013.789566
O'Brien, 2011, Candida infection of the central nervous system following neurosurgery: a 12-year review, Acta Neurochir (Wien), 153, 1347, 10.1007/s00701-011-0990-9
Aleixo, 2000, Candida albicans meningitis: clinical case, J Infect, 40, 191, 10.1016/S0163-4453(00)80017-1
Epelbaum, 1993, Failure of fluconazole treatment in Candida meningitis, J Pediatr, 123, 168, 10.1016/S0022-3476(05)81571-9
Liu, 2004, Refractory candidal meningitis in an immunocompromised patient cured by caspofungin, J Clin Microbiol, 42, 5950, 10.1128/JCM.42.12.5950-5953.2004
Prabhu, 2004, Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis, Clin Infect Dis, 39, 1253, 10.1086/424449
Pepper, 2013, The risk of hardware infection in deep brain stimulation surgery is greater at impulse generator replacement than at the primary procedure, Stereotact Funct Neurosurg, 91, 56, 10.1159/000343202
Glick, 2010, Candida meningitis post Gliadel wafer placement successfully treated with intrathecal and intravenous amphotericin B, Ann Pharmacother, 44, 215, 10.1345/aph.1M453
Achkar, 2010, Candida infections of the genitourinary tract, Clin Microbiol Rev, 23, 253, 10.1128/CMR.00076-09
Kauffman, 2000, Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group, Clin Infect Dis, 30, 14, 10.1086/313583
Chen, 2008, Clinician response to Candida organisms in the urine of patients attending hospital, Eur J Clin Microbiol Infect Dis, 27, 201, 10.1007/s10096-007-0427-9
Kobayashi, 2004, Candiduria in hospital patients: a study prospective, Mycopathologia, 158, 49, 10.1023/B:MYCO.0000038436.51918.d9
Sobel, 2011, Candida urinary tract infections—epidemiology, Clin Infect Dis, 52, S433, 10.1093/cid/cir109
Fraisse, 2011, Candiduria in those over 85 years old: a retrospective study of 73 patients, Intern Med, 50, 1935, 10.2169/internalmedicine.50.5560
Simpson, 2004, The effect of current management on morbidity and mortality in hospitalised adults with funguria, J Infect, 49, 248, 10.1016/j.jinf.2003.08.008
Binelli, 2006, Investigation of the possible association between nosocomial candiduria and candidaemia, Clin Microbiol Infect, 12, 538, 10.1111/j.1469-0691.2006.01435.x
Bougnoux, 2008, Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome, Intensive Care Med, 34, 292, 10.1007/s00134-007-0865-y
Alvarez-Lerma, 2003, Candiduria in critically ill patients admitted to intensive care medical units, Intensive Care Med, 29, 1069, 10.1007/s00134-003-1807-y
Paul, 2007, Factors associated with candiduria and related mortality, J Infect, 55, 450, 10.1016/j.jinf.2007.06.010
Viale, 2009, Candida colonization and candiduria in critically ill patients in the intensive care unit, Drugs, 69, 51, 10.2165/11315640-000000000-00000
Safdar, 2005, Predictors and outcomes of candiduria in renal transplant recipients, Clin Infect Dis, 40, 1413, 10.1086/429620
Robinson, 2009, Characteristics and outcome of infants with candiduria in neonatal intensive care—a Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study, BMC Infect Dis, 9, 183, 10.1186/1471-2334-9-183
Georgiadou, 2013, Candiduria in haematologic malignancy patients without a urinary catheter: nothing more than a frailty marker?, Mycoses, 56, 311, 10.1111/myc.12024
Ang, 1993, Candidemia from a urinary tract source: microbiological aspects and clinical significance, Clin Infect Dis, 17, 662, 10.1093/clinids/17.4.662
Beck, 2008, Fungal urosepsis after ureteroscopy in cirrhotic patients: a word of caution, Urology, 72, 291, 10.1016/j.urology.2008.01.005
Fisher, 2011, Candida urinary tract infection: pathogenesis, Clin Infect Dis, 52, S437, 10.1093/cid/cir110
Sobel, 2002, Controversies in the diagnosis of candiduria: what is the critical colony count?, Curr Treatment Options Infect Dis, 4, 81
Kauffman, 2011, Candida urinary tract infections—diagnosis, Clin Infect Dis, 52, S452, 10.1093/cid/cir111
Sadegi, 2009, Primary renal candidiasis: importance of imaging and clinical history in diagnosis and management, J Ultrasound Med, 28, 507, 10.7863/jum.2009.28.4.507
Erden, 2000, Radiological findings in the diagnosis of genitourinary candidiasis, Pediatr Radiol, 30, 875, 10.1007/s002470000351
Krishnasamy, 2010, Emphysematous pyelonephritis caused by Candida tropicalis, Am J Med, 123, e7, 10.1016/j.amjmed.2009.07.024
Wise, 2006, How to diagnose and treat fungal infections in chronic prostatitis, Curr Urol Rep, 7, 320, 10.1007/s11934-996-0012-2
Jenkin, 1998, Candidal epididymo-orchitis: case report and review, Clin Infect Dis, 26, 942, 10.1086/513937
Wen, 2012, Emphysematous prostatic abscess: case series study and review, Int J Infect Dis, 16, e344, 10.1016/j.ijid.2012.01.002
Sobel, 2000, Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group, Clin Infect Dis, 30, 19, 10.1086/313580
Fisher, 2003, Efficacy of a single intravenous dose of amphotericin B for Candida urinary tract infections: further favorable experience, Clin Microbiol Infect, 9, 1024, 10.1046/j.1469-0691.2003.00711.x
Agustin, 1999, Failure of a lipid amphotericin B preparation to eradicate candiduria: preliminary findings based on three cases, Clin Infect Dis, 29, 686, 10.1086/598658
Sobel, 2007, Caspofungin in the treatment of symptomatic candiduria, Clin Infect Dis, 44, e46, 10.1086/510432
Haruyama, 2006, Candida glabrata fungemia in a diabetic patient with neurogenic bladder: successful treatment with micafungin, Clin Nephrol, 66, 214, 10.5414/CNP66214
Malani, 2010, Failure of caspofungin for treatment of Candida glabrata candiduria. Case report and review of the literature, Infect Dis Clin Pract, 18, 271, 10.1097/IPC.0b013e3181d04a1d
Schelenz, 2006, Limitations of caspofungin in the treatment of obstructive pyonephrosis due to Candida glabrata infection, BMC Infect Dis, 6, 126, 10.1186/1471-2334-6-126
Jacobs, 1994, Bladder irrigation with amphotericin B for treatment of fungal urinary tract infections, Clin Infect Dis, 18, 313, 10.1093/clinids/18.3.313
Leu, 1995, Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study, Clin Infect Dis, 20, 1152, 10.1093/clinids/20.5.1152
Jacobs, 1996, Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients, Clin Infect Dis, 22, 30, 10.1093/clinids/22.1.30
Drew, 2005, Is it time to abandon the use of amphotericin B bladder irrigation?, Clin Infect Dis, 40, 1465, 10.1086/429722
Tuon, 2009, Bladder irrigation with amphotericin B and fungal urinary tract infection—systematic review with meta-analysis, Int J Infect Dis, 13, 701, 10.1016/j.ijid.2008.10.012
Chitale, 2004, Endoscopic management of renal candidiasis, J Endourol, 18, 865, 10.1089/end.2004.18.865
Davis, 2013, Ureteric obstruction due to fungus-ball in a chronically immunosuppressed patient, Can Urol Assoc J, 7, E355, 10.5489/cuaj.1214
Vazquez-Tsuji, 2005, Renal ultrasonography and detection of pseudomycelium in urine as means of diagnosis of renal fungus balls in neonates, Mycopathologia, 159, 331, 10.1007/s11046-004-3713-4
Shih, 2005, Percutaneous extraction of bilateral renal mycetomas in premature infant using mechanical thrombectomy device, Urology, 65, 1226, 10.1016/j.urology.2004.12.008
Babu, 2004, Renal fungal balls and pelvi-ureteric junction obstruction in a very low birth weight infant: treatment with streptokinase, Pediatr Surg Int, 20, 804, 10.1007/s00383-004-1301-9
Chung, 2001, Successfully treated renal fungal ball with continuous irrigation of fluconazole, J Urol, 166, 1835, 10.1016/S0022-5347(05)65693-5
Sobel, 1998, Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations, Am J Obstet Gynecol, 178, 203, 10.1016/S0002-9378(98)80001-X
Reef, 1995, Treatment options for vulvovaginal candidiasis, 1993, Clin Infect Dis, 20, S80, 10.1093/clinids/20.Supplement_1.S80
Watson, 2002, Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review, BJOG, 109, 85, 10.1111/j.1471-0528.2002.01142.x
Sobel, 1995, Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group, Am J Obstet Gynecol, 172, 1263, 10.1016/0002-9378(95)91490-0
Sood, 2000, Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis, Infect Dis Obstet Gynecol, 8, 240, 10.1002/1098-0997(2000)8:5<240::AID-IDOG1026>3.0.CO;2-4
Sobel, 2003, Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine, Am J Obstet Gynecol, 189, 1297, 10.1067/S0002-9378(03)00726-9
White, 2001, Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections, Sex Transm Infect, 77, 212, 10.1136/sti.77.3.212
Marchaim, 2012, Fluconazole-resistant Candida albicans vulvovaginitis, Obstet Gynecol, 120, 1407, 10.1097/AOG.0b013e31827307b2
Sobel, 2004, Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis, N Engl J Med, 351, 876, 10.1056/NEJMoa033114
Donders, 2008, Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial), Am J Obstet Gynecol, 199, 613e1, 10.1016/j.ajog.2008.06.029
Rosa, 2013, Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis, Eur J Obstet Gynecol Reprod Biol, 167, 132, 10.1016/j.ejogrb.2012.12.001
Witt, 2009, Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial, BJOG, 116, 1499, 10.1111/j.1471-0528.2009.02262.x
Iavazzo, 2011, Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence, J Womens Health (Larchmt), 20, 1245, 10.1089/jwh.2010.2708
Bodhade, 2011, Oral manifestations of HIV infection and their correlation with CD4 count, J Oral Sci, 53, 203, 10.2334/josnusd.53.203
Schwarcz, 2013, Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance, AIDS, 27, 597, 10.1097/QAD.0b013e32835b0fa2
Sangeorzan, 1994, Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance, Am J Med, 97, 339, 10.1016/0002-9343(94)90300-X
Patel, 2012, The changing epidemiology of oropharyngeal candidiasis in patients with HIV/AIDS in the era of antiretroviral therapy, AIDS Res Treat, 2012, 262471
Bonacini, 1991, The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients, Arch Intern Med, 151, 1567, 10.1001/archinte.1991.00400080067012
Pons, 1993, Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group, J Acquir Immune Defic Syndr, 6, 1311
Finlay, 1996, A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours, Br J Oral Maxillofac Surg, 34, 23, 10.1016/S0266-4356(96)90130-8
Vazquez, 2010, Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad(R) efficacy and safety (SMiLES), HIV Clin Trials, 11, 186, 10.1310/hct1104-186
Cartledge, 1997, Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis, J Clin Pathol, 50, 477, 10.1136/jcp.50.6.477
Queiroz-Telles, 2001, Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in AIDS patients, Braz J Infect Dis, 5, 60, 10.1590/S1413-86702001000200003
Phillips, 1998, A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS, Clin Infect Dis, 26, 1368, 10.1086/516342
Vazquez, 2006, A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS, Clin Infect Dis, 42, 1179, 10.1086/501457
Havlir, 1998, Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS, Clin Infect Dis, 27, 1369, 10.1086/515018
Meunier, 1994, Value of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients, Eur J Cancer B Oral Oncol, 30B, 196, 10.1016/0964-1955(94)90091-4
Philpott-Howard, 1993, Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group, J Antimicrob Chemother, 31, 973, 10.1093/jac/31.6.973
Smith, 1999, A randomised, double-blind study of itraconazole versus placebo in the treatment and prevention of oral or oesophageal candidosis in patients with HIV infection, Int J Clin Pract, 53, 349, 10.1111/j.1742-1241.1999.tb11744.x
Phillips, 1996, Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility, AIDS, 10, 1369, 10.1097/00002030-199610000-00009
Saag, 1999, Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients, AIDS Res Hum Retroviruses, 15, 1413, 10.1089/088922299309919
Skiest, 2007, Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection, Clin Infect Dis, 44, 607, 10.1086/511039
Hegener, 1998, Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS, AIDS, 12, 2227
Villanueva, 2002, A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis, Am J Med, 113, 294, 10.1016/S0002-9343(02)01191-9
Dewsnup, 1994, Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole, J Med Vet Mycol, 32, 389, 10.1080/02681219480000511
Vazquez, 2000, Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study, HIV Clin Trials, 1, 23, 10.1310/LF5T-WYY7-0U3E-G8BQ
Bodasing, 2002, Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient, J Antimicrob Chemother, 50, 765, 10.1093/jac/dkf206
Martins, 1998, Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients, Clin Infect Dis, 27, 1291, 10.1086/515006
Kirkpatrick, 1979, Mucocutaneous candidiasis and thymoma, Am J Med, 66, 939, 10.1016/0002-9343(79)90448-0
Kamai, 2004, Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis, Microbiol Immunol, 48, 937, 10.1111/j.1348-0421.2004.tb03623.x
Wilcox, 1996, Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms, Gastroenterology, 110, 1803, 10.1053/gast.1996.v110.pm8964406
Barbaro, 1996, Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida esophagitis, Gastroenterology, 111, 1169, 10.1053/gast.1996.v111.pm8898629
Wilcox, 1997, A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis, J Infect Dis, 176, 227, 10.1086/514028